Anti free radical & anti inflammatory effect of rebamipide in chronic gastritis

Marcellus Simadibrata, Ari Fahrial Syam, Aziz Rani, Septelia Inawati Wanandi, Achmad Fauzi, Murdani Abdullah

Department of Biochemistry, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Gastroenterology Division, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Depok, Indonesia.

DOI: 10.4236/ojgas.2013.31011                

Abstract

Background/Aim: Free radicals have a role in the development of chronic gastritis. The aim of this study to know the effect and efficacy of rebamipide on free radicals in chronic gastritis. Method: Forty five patients in the division gastroenterology Cipto Mangunkusumo Hospital Jakarta 2009-2010 with moderate and severe gastritis endoscopically were included in this study. Before and after rebamipide treatment the patient were performed endoscopical examination and were taken 5 biopsies for histopathological examination and free radicals (MDA & Carbonyl Compound) examination. All patients were given rebamipide 100 mg three times a day for 28 days. Data were analyzed with t test or wilcoxon signed rank test. Exclusion: GERD, Peptic ulcer, PPI treatment, NSAID consumption etc. The symptoms were recorded on day-0 and day-28. The severity symptoms were measured by VAS. Result: The mucosal damage on day-0 was 2.268 ± 0.45 vs day-28 was 1.707 ± 0.78 (P < 0.001). The antrum neutrophil: day-0: 0.12 ± 0.46 vs day-28: 0.10 ± 0.37 (P = 0.710) and corpus neutrophil: day-0: 0.12 ± 0.40 vs day-28: 0.07 ± 0.26 (P = 0.421). The mean endoscopical mucosal severity score was decreased significantly on day- 28 compared to day-0 (1.707 ± 0.78 vs 2.268 ± 0.45; P < 0.05). The other histopathological appearances between day-0 and day-28 were not different. Rebamipide can reduce the mean of MDA from 5.28 ± 3.54 on day-0 to 4.15 ± 2.71 on day-28 (P = 0.047). The mean of carbonyl compound on day-0 was 4.14 ± 3.01 and on day-28 was 5.12 ± 2.71 (P = 0.642). Conclusion: Rebamipide significantly reduced the extend of symptoms associated with chronic gastritis. The improvement in symptoms was associated with the decreased of endoscopic severity score and the mean gastric mucosal malondialdehyde (MDA) significantly but not the histopathologic appearance and carbonyl compound.

Keywords

Rebamipide; Chronic Gastritis; Histopathologic Severity; MDA; Carbonyl Compound

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Santra, A., Chowdhury, A., Chaudhury, S., et al. (2000) Oxidative stress in gastric mucosa in Helicobacter pylori infection. Indian Journal of Gastroenterology, 19, 21-23.
[2]	Hayashi, S., Sugiyama, T., Amano, K., Isogai, H., Isogai, E., Aihara, M., et al. (1998) Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrobial Agents and Chemotherapy, 42, 1895-1889.
[3]	Urita, Y., Watanabe, T., Maeda, T., Sasaki, Y., Hike, K., Muto, H., et al. (2009) Rebamipide and mosapride enhance pilocarpine-induced salivation. North American Journal of Medical Sciences, 1, 121-124.
[4]	Chey, W.D. and Wong, B.C. (2007) Practice parameters committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. American Journal of Gastroenterology, 102, 1808-1825. doi:10.1111/j.1572-0241.2007.01393.x
[5]	Chitapanarux, T., Praisontarangkul, O.A. and Lertpraser tsuke, N. (2008) An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Digestive Diseases and Sciences, 53, 2896-2903. doi:10.1007/s10620-008-0255-5
[6]	Naito, Y., Yoshikawa, T., Tanigawa, T., et al. (1995) Hydroxyl radical scavenging by rebamipide and related compounds: Electron paramagnetic resonance study. Free Radical Biology & Medicine, 18, 117-123. doi:10.1016/0891-5849(94)00110-6
[7]	Arakawa, T., Kobayashi, K., Yoshikawa, T., Tarnawski, A. (1998) Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Digestive Diseases and Sciences, 43, 5S-13S.
[8]	Rugge, M. and Genta, R.M. (2005) Staging and grading of chronic gastritis. Human Pathology, 36, 228-233. doi:10.1016/j.humpath.2004.12.008
[9]	Naito, Y., Yoshikawa, T., Iinuma, S., Yagi, N., Matsu yama, K., Boku, Y., Fujii, T., Yoshida, N., Kondo, M. and Sasaki, E. (1998) Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in double-blind, placebo-controlled study. Digestive Diseases and Sciences, 43, 83S-89S.
[10]	Higuchi, K., Arakawa, T., Nebiki, H., Uchida, T., Fujiwara, Y., et al. (1998) Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Digestive Diseases and Sciences, 43, S99-S106.
[11]	Miwa, T., Osada, T., Nagahara, A., Ohsuka, T., Hojo, M., Tomita, T., et al. (2006) Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: A double-blind placebo-controlled study in Japan. Journal of Gastroenterology and Hepatology, 21, 1826-1831. doi:10.1111/j.1440-1746.2006.04446.x
[12]	Jeffery, P.L., McGuckin, M.A. and Linde, S.K. (2011) Endocrine impact of Helicobacter pylori: Focus on ghrelin and ghrelin o-acyltransferase. World Journal of Gastroenterology, 17, 1249-1260. doi:10.3748/wjg.v17.i10.1249
[13]	Du, Y., Li, Z., Zhan, X., Chen, J. and Gao, J. (2008) Anti inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: A randomized sucralfate-controlled multicenter trial in China-STARS study. Digestive Diseases and Sciences, 53, 2886-2895. doi:10.1007/s10620-007-0180-z
[14]	Everett, S.M., Singh, R., Leuratti, C. et al. (2001) Levels of malondialdehyde-deoxyguanosine in the gastric mucosa: Relationship with lipid peroxidation, ascorbic acid, and Helicobacter pylori. Cancer Epidemiology, Biomarkers & Prevention, 10, 369-376.
[15]	Naito, Y., Takagi, T., Okada, H., et al. (2009) Impaired gastric ulcer healing in diabetic mice: Role of methylglyoxal. Journal of Physiology and Pharmacology, 60, 123-130.